Inducing tumoral ferroptosis is a potential strategy for augmenting cancer immunotherapy. A recent study reveals that PSAT1-mediated GPX4 hydroxylation in response to IFNγ stimulation impedes tumoral ferroptosis, whereas disrupting the PSAT1–GPX4 interaction can improve the efficacy of cancer immunotherapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dixon, S. J. et al. Cell 149, 1060–1072 (2012).
Yang, W. S. et al. Cell 156, 317–331 (2014).
Zheng, P. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-025-01887-3 (2025).
Wang, W. et al. Nature 569, 270–274 (2019).
Liao, P. et al. Cancer Cell 40, 365–378.E6 (2022).
Wu, Z. et al. Proc. Natl Acad. Sci. USA 116, 2996–3005 (2019).
Matsushita, M. et al. J. Exp. Med. 212, 555–568 (2015).
Li, S. et al. Cell Discov. 10, 53 (2024).
Li, H. et al. Proc. Natl Acad. Sci. USA 121, e2315541121 (2024).
Wu, K. et al. Nat. Cell Biol. 25, 714–725 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Li, J., Zhou, Y. & Wang, W. Interfering with GPX4 degradation. Nat Chem Biol 21, 1308–1309 (2025). https://doi.org/10.1038/s41589-025-01873-9
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41589-025-01873-9
